Search by Drug Name or NDC
NDC 52652-8001-01 ZONISADE 100 mg/5mL Details
ZONISADE 100 mg/5mL
ZONISADE is a ORAL SUSPENSION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Azurity Phramaceuticals, Inc.. The primary component is ZONISAMIDE.
MedlinePlus Drug Summary
Zonisamide is used in combination with other medications to treat certain types of seizures. Zonisamide is in a class of medications called anticonvulsants. It works by decreasing abnormal electrical activity in the brain.
Related Packages: 52652-8001-01Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Zonisamide
Product Information
| NDC | 52652-8001 |
|---|---|
| Product ID | 52652-8001_df27963d-6762-4aee-9d48-f5d33ae5ff66 |
| Associated GPIs | |
| GCN Sequence Number | 083589 |
| GCN Sequence Number Description | zonisamide ORAL SUSP 100 MG/5ML ORAL |
| HIC3 | H4B |
| HIC3 Description | ANTICONVULSANTS |
| GCN | 52582 |
| HICL Sequence Number | 021140 |
| HICL Sequence Number Description | ZONISAMIDE |
| Brand/Generic | Brand |
| Proprietary Name | ZONISADE |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | ZONISAMIDE |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | SUSPENSION |
| Route | ORAL |
| Active Ingredient Strength | 100 |
| Active Ingredient Units | mg/5mL |
| Substance Name | ZONISAMIDE |
| Labeler Name | Azurity Phramaceuticals, Inc. |
| Pharmaceutical Class | Anti-epileptic Agent [EPC], Carbonic Anhydrase Inhibitors [MoA], Decreased Central Nervous System Disorganized Electrical Activity [PE], P-Glycoprotein Inhibitors [MoA], Sulfonamides [CS] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA214273 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 52652-8001-01 (52652800101)
| NDC Package Code | 52652-8001-1 |
|---|---|
| Billing NDC | 52652800101 |
| Package | 1 BOTTLE in 1 CARTON (52652-8001-1) / 150 mL in 1 BOTTLE |
| Marketing Start Date | 2022-07-15 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 2.3477 |
| Pricing Unit | ML |
| Effective Date | 2024-01-01 |
| NDC Description | ZONISADE 100 MG/5 ML ORAL SUSP |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 4, 5 |
| Classification for Rate Setting | B |
| As of Date | 2024-02-21 |
This pricing file, entitled the NADAC (National Average Drug Acquisition
Cost) files, provide
state Medicaid agencies with covered outpatient drug prices by averaging
survey invoice
prices from retail community pharmacies across the United States. These
pharmacies include
independent retail community pharmacies and chain pharmacies. The prices
are updated on a
weekly and monthly basis